ArticleDiagnostic pathology2014
High expression of microRNA-130b correlates with poor prognosis of patients with hepatocellular carcinoma.
Article in Diagnostic pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test.Journal of translational medicine · 2019Pooled it
- Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.PloS one · 2020Trial
- Independent Prognosis Prediction of Hepatocellular Carcinoma Using MicroRNA-Based Single and Combined Biomarkers.Canadian journal of gastroenterology & hepatology · 2026Review
- Role of miR-15b and miR-130b as Non-Invasive Biomarkers in Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Independent prognostic significance of tissue and circulating microrna biomarkers in hepatocellular carcinoma.Discover oncology · 2025Review
- Differential Hepatic Expression of miRNA in Response to Aflatoxin B1 Challenge in Domestic and Wild Turkeys.Toxins · 2024Article
- An engineered miRNA PS-OMe miR130 inhibits acute lung injury by targeting eCIRP in sepsis.Molecular medicine (Cambridge, Mass.) · 2023Article
- MiR-130b modulates the invasive, migratory, and metastatic behavior of leiomyosarcoma.PloS one · 2023Article
- Clinical Significance of MiR-130b and MiR-125b as Biomarkers in Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- A Pyroptosis-Related Gene Signature to Predict Patients' Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma.Computational and mathematical methods in medicine · 2022Article
- MicroRNA-130b functions as an oncogene and is a predictive marker of poor prognosis in lung adenocarcinoma.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Extracellular microRNA 130b-3p inhibits eCIRP-induced inflammation.EMBO reports · 2020Article
- Article
- MicroRNA-130b promotes proliferation and EMT-induced metastasis via PTEN/p-AKT/HIF-1α signaling.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions.Scientific reports · 2015Article
- Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.World journal of gastroenterology · 2015Review
- Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma.Diagnostic pathology · 2014Article
- MicroRNA-130b promotes cell aggressiveness by inhibiting peroxisome proliferator-activated receptor gamma in human hepatocellular carcinoma.International journal of molecular sciences · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhether microRNA-130b(miR-130b) can serve as a prognostic biomarker of hepatocellular carcinoma (HCC) has not been investigated. In the present study, we investigated the feasibility of miR-130b as a novel prognostic biomarker for HCC.
methodsWe retrospectively investigated 97 patients diagnosed with HCC who underwent routine curative surgery between May 2007 and July 2012. miR-130b expression in HCC tissues and paired normal adjacent liver tissues was measured by reverse transcription and real-time PCR (RT-PCR). Survival curves were plotted using the Kaplan-Meier method and differences in survival rates were analyzed using the log-rank test.
resultsmiR-130b expression level was significantly higher in HCC tissues compared with normal adjacent liver tissues (P<0.0001). The 5-year overall survival (OS) of high miR-130b expression group was significantly shorter than that of low miR-130b expression group (43.6% vs. 71.5%; P=0.022). Moreover, the 5-year disease-free survival (DFS) of high miR-130b expression group was also significantly shorter than that of low miR-130b expression group (25.9% vs. 63.9%; P=0.012). In a multivariate Cox model, we found that miR-130b expression was an independent prognostic factor for both 5-year OS (hazards ratio [HR] =2.523, 95% confidence interval [CI] =1.024-7.901, P=0.011) and 5-year DFS (HR=4.003, CI=1.578-7.899, P=0.005) in HCC.
conclusionThe results indicated that high expression of microRNA-130b was correlated with significant characteristics of patients with HCC, and it might be useful as a novel prognostic biomarker for HCC. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_160.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.